Cipla Announces Leadership Change, USD 100 Million Investment, Approves Inzpera Merger
New Delhi: Cipla Limited has announced key board decisions including leadership changes, a USD 100 million investment in its subsidiary, and approval of a merger involving its wholly owned unit.
The company has designated its Lead Independent Director, P R Ramesh, as Vice-Chairman with effect from April 1, 2026. At the same time, Robert Stewart has expressed his intention not to seek re-appointment for a second term upon completion of his current tenure on May 13, 2026.
Further, the Board approved an investment of up to $100 million in Cipla (EU) Limited, a wholly owned subsidiary. The investment will be utilised for providing onward financial assistance to InvaGen Pharmaceuticals Inc. to meet its capital expenditure, working capital requirements and other general corporate purposes.
Cipla (EU) Limited, incorporated in the United Kingdom, functions as a holding company for the group’s operations in Europe and emerging markets. As per available financials for FY 2024-25, the entity reported a turnover of USD 3.76 crore and profit after tax of USD 0.60 crore.
In addition, the company has approved a Scheme of Amalgamation of Inzpera Healthsciences Limited, its wholly owned subsidiary, with Cipla Limited. The proposed merger is subject to necessary statutory approvals, including that of the National Company Law Tribunal (NCLT), Mumbai.
The company stated that the amalgamation will not have any material impact on its financials. The move is aimed at streamlining the group structure, reducing administrative costs and improving operational efficiencies. The pediatric pharmaceutical portfolio of Inzpera is aligned with Cipla’s business, and the merger is expected to strengthen its presence in this segment.
As per the scheme, no shares will be issued or allotted, and all shares held by Cipla in Inzpera will stand cancelled upon the scheme becoming effective. There will be no change in the shareholding pattern of the company.
According to the company, the decisions were taken at the Board meeting held on March 19, 2026, in compliance with SEBI Listing Regulations.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.